Medscape

Lecanemab Preserves Memory Over 4 Years in Early Alzheimer’s

Continuous treatment with lecanemab (Leqembi, Eisai/Biogen) demonstrated sustained disease-modifying benefit over 4 years in patients with early-stage Alzheimer’s disease (AD) enrolled in the ...
Benzinga.com

Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years

Anavex Life Sciences Corp. (NASDAQ:AVXL) on Saturday announced that over three years of continuous treatment with blarcamesine (ANAVEX 2-73) demonstrated significant amelioration on clinical decline, ...
Health Affairs

Unwinding And The Medicaid Undercount: Millions Enrolled In Medicaid During The Pandemic Thought They Were Uninsured

Dong Ding ([email protected]), New York University, New York, New York. Benjamin D. Sommers, Harvard University, Boston, Massachusetts. Sherry A. Glied, New York University. Policy responses to the ...
Nursery World

Early years settings invited to take part in survey on woodwork provision

Early years settings that offer woodwork provision for children are being urged to take part in a survey to determine its educational value. The survey forms part of a seven-year international ...
Healio

Donanemab improves outcomes in early-stage Alzheimer’s disease up to 3 years

Please provide your email address to receive an email when new articles are posted on . Earlier initiation of donanemab reduced the risk of disease progression on the Clinical Dementia Rating-Global ...